The latest selling price information of domestic deuterated colexitinib tablets

Deucravacitinib is a selective tyrosine kinase 2 inhibitor mainly used to treat moderate to severe plaque psoriasis. This new type of drug modulates the immune system by targeting specific signaling pathways, thereby reducing inflammation and skin damage. The efficacy of deuterated colexitinib has been verified in multiple clinical trials, showing better safety and tolerability compared with traditional treatments. Therefore, it provides a new treatment option for psoriasis patients, especially those who are refractory to or intolerant to other treatments.

In China, the original research version of deuterated colexitinib has been launched and is included in medical insurance, which is important good news for patients. According to the latest information, the price of deuterated colexitinib tablets (6mg*7 tablets) is about more than 1,000 yuan, which reduces the financial burden on patients when receiving treatment. In addition, the original research version of 6 mg 30 tablets is priced at about 50,000 yuan. The price may change due to exchange rate fluctuations, but overall, it is still a relatively high treatment cost.

It is worth noting that in addition to the original drug, countries such as Laos and Bangladesh also have generic versions of deuterated colexitinib that are officially on the market. The ingredients of these generic drugs are basically the same as those of the original drugs, so they are also similar in efficacy and safety. Taking 6mg*30 tablets as an example, the price of these generic drugs may be around four to five hundred yuan, which is significantly lower than the price of the original drug. This provides patients with more options, especially when financial conditions are limited.

As deuterated colexitinib is promoted on the market, more and more patients will have access to this new treatment. At the same time, the launch of generic drugs will also help increase competition and promote the gradual rationalization of drug prices so that more patients can afford treatment.

Reference materials:https://go.drugbank.com/drugs/DB16650